• ქართული
  • English
  • Novartis bets big on gene therapy with $8.7 billion AveXis deal

    ZURICH (Reuters) – Novartis is moving further into gene therapy with a $8.7 billion deal for AveXis that gives the Swiss drugmaker a rare-disease treatment seen reaping billions in sales and bolsters its technology base.

    Market Quotes by TradingView